1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Galapagos' FLORA: Highly Positive Hints In IPF, But More To Prove

 
• By Alexandra Shimmings

Mid-stage research in idiopathic pulmonary fibrosis is getting interesting, with Galapagos' GLPG1690 the second novel treatment to report promising data in the space of a few days. Blockbuster sales await.

Lungs
• Source: Shutterstock

Galapagos NV reported "extremely exciting" Phase IIa data from the FLORA study for its investigational therapy GLPG1690 for the rare and difficult-to-treat lung disease idiopathic pulmonary fibrosis (IPF), and for the company, it's a second proof-of-concept result for its discovery platform.

While a small study, FLORA suggested that the drug – a first-in-class small-molecule autotaxin inhibitor – stabilized lung function in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

More from R&D